文献速递肝肾功能剂量调整药物相互作用

pevonedistat单药或联合标准治疗在实体瘤或血液恶性肿瘤患者中的群体药代动力学

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
PubMed 文献 · Br J Clin Pharmacol · 2019-09-04

该群体药代动力学分析 pooled 6项临床研究335例实体瘤或血液恶性肿瘤患者,评估pevonedistat单药或联合阿扎胞苷、多西他赛、卡铂+紫杉醇或吉西他滨的PK。最终模型为线性二室模型,BSA影响清除率和分布容积,卡铂+紫杉醇使CL降低约44%,模拟支持基于BSA给药以减少暴露个体间变异。

要点

  • BSA在1.38-3 m²范围内变化时,所有PK参数变化≥20%,CL为参考值的75.5%-208%。
  • 卡铂+紫杉醇联合给药使pevonedistat CL降低约44%,其他联合用药未改变CL。
  • 轻中度肾损害(CrCl≥30 mL/min)或轻度肝损害、种族、性别、年龄、肿瘤类型不影响PK。

核心结论

  • pevonedistat在实体瘤与血液恶性肿瘤患者中的临床PK特征相当。
  • BSA基于给药可最小化药物暴露的个体间变异。
  • 卡铂+紫杉醇联合给药使pevonedistat清除率降低约44%。

研究设计与样本

  • 群体药代动力学分析,pooled 6项临床研究共335例实体瘤或血液恶性肿瘤患者。
  • 患者接受pevonedistat单药或联合阿扎胞苷、多西他赛、卡铂+紫杉醇或吉西他滨。
  • 采用非线性混合效应模型建模,参数及bootstrap 95%CI估计,最终模型用视觉预测检查等评价。

主要发现

  • 线性二室模型最佳描述pevonedistat PK。
  • 最终模型包含BSA对CL、Q及分布容积的影响,卡铂+紫杉醇对CL的影响,白蛋白对Q的影响。
  • BSA范围1.38-3 m²内所有PK参数变化≥20%,CL为参考值的75.5%-208%。
  • 卡铂+紫杉醇使CL降低约44%,阿扎胞苷、吉西他滨或多西他赛未改变CL。
  • 种族、性别、年龄、肿瘤类型、轻中度肾损害(CrCl≥30 mL/min)或轻度肝损害对PK无影响。

关键数值与推荐

  • BSA范围1.38-3 m²,CL变化范围为参考值的75.5%-208%。
  • 卡铂+紫杉醇联合给药使pevonedistat CL降低约44%。
  • 轻中度肾损害定义为肌酐清除率≥30 mL/min。

临床怎么用

  • 临床可考虑基于BSA给药以减小pevonedistat暴露的个体间变异。
  • 与卡铂+紫杉醇联合用药时需注意pevonedistat清除率降低约44%的可能影响。
  • 轻中度肾损害或轻度肝损害患者及不同种族、性别、年龄、肿瘤类型无需基于PK调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK. METHODS: Data were pooled from 6 clinical studies consisting of 335 patients with solid tumours or haematological malignancies administered pevonedistat alone or in combination with azacitidine, docetaxel, carboplatin + paclitaxel, or gemcitabine. Model development and covariate analysis followed standard methods. Parameters and bootstrap 95% confidence intervals were estimated using nonlinear mixed-effects modelling. The final model was evaluated using visual predictive checks and other goodness-of-fit criteria. RESULTS: A linear 2-compartment model best described pevonedistat PK. The final model included the effect of body surface area (BSA) on clearance (CL and Q) and volume of distribution of pevonedistat, effect of concomitantly administered carboplatin + paclitaxel on CL, and effect of albumin on Q. Race, sex, age, tumour type (haematological vs solid), mild or moderate renal impairment (creatinine clearance ≥30 mL/min), or mild hepatic impairment, had no impact on pevonedistat PK. CONCLUSIONS: The clinical PK profile of pevonedistat is comparable in patients with solid tumours or haematological malignancies. All PK parameters exhibited ≥20% change over the observed BSA range (1.38-3 m2 ) with CL ranging from 75.5 to 208% of the reference value, with simulations supporting BSA-based dosing to minimize interindividual variability in drug exposures. Concurrent administration of carboplatin + paclitaxel decreased pevonedistat CL by approximately 44%, while coadministration with azacitidine, gemcitabine or docetaxel did not alter pevonedistat CL. No other factors were identified as influencing pevonedistat PK.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Faessel HM, Mould DR, Zhou X, et al. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019. PMID: 31355467. doi:10.1111/bcp.14078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。